On December 28, 2021, the FDA updated the emergency use authorization (EUA) for COVID-19 convalescent plasma. The update limits the authorization to the use of COVID-19 convalescent plasma with high titers of anti -SARS-CoV-2 antibodies for the treatment of COVID-19 in patients with immunosuppressive disease or who are receiving immunosuppressive treatment. Additionally, to help assure the manufacture of high titer COVID-19 convalescent plasma, the revisions to the EUA define acceptable tests and increase qualifying result cutoffs to be used for manufacturing COVID-19 convalescent plasma with high titers of anti-SARS-CoV-2 antibodies.
We are currently evaluating our options to determine if we can provide additional testing services using one of the newly defined assays. Please reach out to your customer service manager if your organization is considering CCP testing under the updated guidelines.
CTS successfully implemented Donor-Screen HLA® Class I and II testing on the Stratec Biomedical ...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
Just a reminder that the revised client forms implement today! Don't forget to toss your o...
CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The ...
On January 25, 2021, CTS implements the Ortho VIP viral marker testing platform. Conversion from the...
CTS communications distributed on July 6th and July 20th.In working with Grifols on the availability...